Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers

NCT01563302 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01563302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01563302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 27, 2012
Completion date
March 23, 2016
Enrollment
64 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers, dlbcl, lymphoma